Recent approaches of lipid-based delivery system for lymphatic targeting via oral route

被引:115
作者
Chaudhary, Shilpa [1 ]
Garg, Tarun [1 ]
Murthy, R. S. R. [1 ]
Rath, Goutam [1 ]
Goyal, Amit K. [1 ]
机构
[1] ISF Coll Pharm, Dept Pharmaceut, Moga, Punjab, India
关键词
Chylomicron pathway; lipid-based delivery systems; lymphatic delivery; oral bioavailability; FLOW BLOCKING APPROACH; CURRENT NANOTECHNOLOGICAL STRATEGIES; HIGH-DENSITY-LIPOPROTEINS; IN-VITRO LIPOLYSIS; DRUG-DELIVERY; INTESTINAL-ABSORPTION; CHYLOMICRON METABOLISM; FATTY-ACID; TRANSPORT; NANOPARTICLES;
D O I
10.3109/1061186X.2014.950664
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Lymphatic system is a key target in research field due to its distinctive makeup and huge contributing functions within the body. Intestinal lymphatic drug transport (chylomicron pathway) is intensely described in research field till date because it is considered to be the best for improving oral drug delivery by avoiding first pass metabolism. The lymphatic imaging techniques and potential therapeutic candidates are engaged for evaluating disease states and overcoming these conditions. The novel drug delivery systems such as self-microemulsifying drug delivery system, nanoparticles, liposomes, nano-lipid carriers, solid lipid carriers are employed for delivering drugs through lymphatic system via various routes such as subcutaneous route, intraperitoneal route, pulmonary route, gastric sub-mucosal injection, intrapleural and intradermal. Among these colloidal particles, lipid-based delivery system is considered to be the best for lymphatic delivery. From the last few decades, mesenteric lymph duct cannulation and thoracic lymph duct cannulation are followed to assess lymphatic uptake of drugs. Due to their limitations, chylomicrons inhibitors and in-vitro models are employed, i.e. lipolysis model and permeability model. Currently, research on this topic still continues and drainage system used to deliver the drugs against lymphatic disease as well as targeting other organs by modulating the chylomicron pathway.
引用
收藏
页码:871 / 882
页数:12
相关论文
共 107 条
[1]   Intestinal DGAT1 deficiency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying [J].
Ables, Gene P. ;
Yang, Kryscilla Jian Zhang ;
Vogel, Silke ;
Hernandez-Ono, Antonio ;
Yu, Shuiqing ;
Yuen, Jason J. ;
Birtles, Susan ;
Buckett, Linda K. ;
Turnbull, Andrew V. ;
Goldberg, Ira J. ;
Blaner, William S. ;
Huang, Li-Shin ;
Ginsberg, Henry N. .
JOURNAL OF LIPID RESEARCH, 2012, 53 (11) :2364-2379
[2]   Direct evidence of lymphatic function improvement after advanced pneumatic compression device treatment of lymphedema [J].
Adams, Kristen E. ;
Rasmussen, John C. ;
Darne, Chinmay ;
Tan, I-Chih ;
Aldrich, Melissa B. ;
Marshall, Milton V. ;
Fife, Caroline E. ;
Maus, Erik A. ;
Smith, Latisha A. ;
Guilloid, Renie ;
Hoy, Sunday ;
Sevick-Muraca, Eva M. .
BIOMEDICAL OPTICS EXPRESS, 2010, 1 (01) :114-125
[3]  
Ak G., 2013, DNA RNA NANOBIOTECHN, P67
[4]   CHEMOTHERAPY TARGETING REGIONAL LYMPH-NODES BY GASTRIC SUBMUCOSAL INJECTION OF LIPOSOMAL ADRIAMYCIN IN PATIENTS WITH GASTRIC-CARCINOMA [J].
AKAMO, Y ;
MIZUNO, I ;
YOTSUYANAGI, T ;
ICHINO, T ;
TANIMOTO, N ;
YAMAMOTO, T ;
NAGATA, M ;
TAKEYAMA, H ;
SHINAGAWA, N ;
YURA, J ;
MANABE, T .
JAPANESE JOURNAL OF CANCER RESEARCH, 1994, 85 (06) :652-658
[5]   Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting [J].
Alex, M. R. Aji ;
Chacko, A. J. ;
Jose, S. ;
Souto, E. B. .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 42 (1-2) :11-18
[6]   Molecular mechanisms of lymphangiogenesis in health and disease [J].
Alitalo, K ;
Carmeliet, P .
CANCER CELL, 2002, 1 (03) :219-227
[7]  
[Anonymous], DRUG DELIV
[8]  
[Anonymous], ARTIF CELLS NANOMED
[9]  
[Anonymous], ARTIF CELLS NANOMED
[10]  
[Anonymous], ARTIF CELLS NANOMED